Form 4: Director M. Kathleen Behrens Receives SRPT Equity Grant

Sarepta Therapeutics director M. Kathleen Behrens was granted 16,875 restricted stock units as part of an equity compensation plan.

Summary

• Director M. Kathleen Behrens acquired 16,875 restricted stock units (RSUs) of Sarepta Therapeutics, Inc. (SRPT) on June 4, 2026.
• Each RSU represents the right to receive one share of common stock upon vesting.
• Following this transaction, the reporting person holds 214,357 shares directly and 10,000 shares indirectly via a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the equity grant is subject to market volatility and the future performance of Sarepta Therapeutics' stock price.

Future Outlook

The RSUs are scheduled to vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided it is at least 50 weeks after the previous year's meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation practices for independent directors in mid-to-large cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 16,875 RSUs upon the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Equity Compensation, Director Ownership